Talk:Beta blocker: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 23:04, 14 November 2017 editCglife.trummler (talk \| contribs)39 editsNo edit summary← Previous edit		Revision as of 23:44, 14 November 2017 edit undoBiochemistry&Love (talk \| contribs)Extended confirmed users, New page reviewers5,950 edits →Other Effects, Beta-adrenergic Receptors: +Next edit →
Line 92:		Line 92:

	This section on non-cardiological indications should be supported, although this citation is admittedly primary research. Do you think this adds reliable, valuable information to this article?] (]) 23:02, 14 November 2017 (UTC)		This section on non-cardiological indications should be supported, although this citation is admittedly primary research. Do you think this adds reliable, valuable information to this article?] (]) 23:02, 14 November 2017 (UTC)
			:I couldn't view the citation. Can you give a DOI?
			:I found a review article on the subject , but I haven't read it. See: Coelho, M., Soares-Silva, C., Brandão, D. et al. ''J Cancer Res Clin Oncol''. 2017;143:275.―] 23:43, 14 November 2017 (UTC)

Revision as of 23:44, 14 November 2017

Ideal sources for Misplaced Pages's health content are defined in the guideline Misplaced Pages:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Beta blocker.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

This is the talk page for discussing improvements to the Beta blocker article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Misplaced Pages? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Archives: 1Auto-archiving period: 2 months

Pharmacology C‑class Top‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
C	This article has been rated as C-class on Misplaced Pages's content assessment scale.
Top	This article has been rated as Top-importance on the project's importance scale.

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

Cglife.trummler (talk · contribs) has been paid by CG Life on behalf of Impact Journals.

Unsourced

Moved here per WP:PRESERVE as this is almost all unsourced. Per WP:BURDEN please do not restore without finding reliable sources, checking the content against them, and citing the sources.

Examples

Dichloroisoprenaline, the first beta blocker

Nonselective agents

Nonselective beta blockers display both β₁ and β₂ antagonism.

Propranolol
Bucindolol (has additional α1-blocking activity)
Carteolol
Carvedilol (has additional α1-blocking activity)
Labetalol (has additional α1-blocking activity)
Nadolol
Oxprenolol (has intrinsic sympathomimetic activity)
Penbutolol (has intrinsic sympathomimetic activity)
Pindolol (has intrinsic sympathomimetic activity)
Sotalol (not considered a "typical beta-blocker")
Timolol

β₁-selective agents

β₁-selective beta blockers are also known as cardioselective beta blockers.

Acebutolol (has intrinsic sympathomimetic activity, ISA)
Atenolol
Betaxolol
Bisoprolol
Celiprolol (has intrinsic sympathomimetic activity)
Metoprolol
Nebivolol

β₂-selective agents

β₃-selective agents

SR 59230A

Comparative information

Pharmacological differences

Agents with intrinsic sympathomimetic action (ISA)
- Acebutolol, pindolol, labetalol, mepindolol, oxprenolol, celiprolol, penbutolol
Agents organized by lipid solubility (lipophilicity)
- High lipophilicity: propranolol, labetalol
- Intermediate lipophilicity: metoprolol, bisoprolol, carvedilol, acebutolol, timolol, pindolol
- Low lipophilicity (also known as hydrophilic beta-blockers): atenolol, nadolol, and sotalol
Agents with membrane stabilizing effect
- Carvedilol, propranolol > oxprenolol > labetalol, metoprolol, timolol

Indication differences

Agents specifically labeled for cardiac arrhythmia
- Esmolol, sotalol, landiolol (Japan)
Agents specifically labeled for congestive heart failure
- Carvedilol, sustained-release metoprolol
Agents specifically labeled for glaucoma
- Betaxolol, carteolol, levobunolol, timolol, metipranolol
Agents specifically labeled for myocardial infarction
- Atenolol, metoprolol (immediate release), propranolol (immediate release), timolol, carvedilol (after left ventricular dysfunction)
Agents specifically labeled for migraine prophylaxis
- Timolol, propranolol

Propranolol is the only agent indicated for control of tremor, portal hypertension, and esophageal variceal bleeding, and used in conjunction with α-blocker therapy in phaeochromocytoma.

References

^ "Comparison of Oral Beta-Blockers". pharmacist.therapeuticresearch.com. Therapeutic Research Center. Retrieved 30 April 2017.
Rosendorff C (1993). "Beta-blocking agents with vasodilator activity". Journal of Hypertension. Supplement. 11 (4): S37–40. doi:10.1097/00004872-199306003-00009. PMID 8104240.
"CARTEOLOL". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
^ "oxprenolol". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
^ "Celiprolol". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
"Butaxamine". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
"ICI 118551 hydrochloride". abcam.com. Abcam plc. Retrieved 18 October 2017.
"SR 59230A". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
^ Larochelle, Pierre; Tobe, Sheldon W.; Lacourcière, Yves (May 2014). "β-Blockers in Hypertension: Studies and Meta-analyses Over the Years". Canadian Journal of Cardiology. 30 (5): S16 – S22. doi:10.1016/j.cjca.2014.02.012. {{cite journal}}: |access-date= requires |url= (help); no-break space character in |title= at position 59 (help)
Mulrow, edited by Detlev Ganten, Patrick J. (1990). Pharmacology of Antihypertensive Therapeutics. Berlin, Heidelberg: Springer Berlin Heidelberg. p. 523. ISBN 9783642742095. {{cite book}}: |access-date= requires |url= (help); |first1= has generic name (help)CS1 maint: multiple names: authors list (link)
Zipursky, Jonathan S.; Macdonald, Erin M.; Luo, Jin; Gomes, Tara; Mamdani, Muhammad M.; Paterson, J. Michael; Juurlink, David N. (June 2017). "Lipophilic β-Blockers and Suicide in the Elderly". Journal of Clinical Psychopharmacology. 37 (3): 381–384. doi:10.1097/JCP.0000000000000695. Retrieved 18 October 2017.
^ Aronson, Jeffrey K (1 June 2008). "Changing beta-blockers in heart failure: when is a class not a class?". British Journal of General Practice. 58 (551): 387–389. doi:10.3399/bjgp08X299317. {{cite journal}}: |access-date= requires |url= (help)
"BREVIBLOC (esmolol hydrochloride)". Baxter Healthcare Corporation. {{cite web}}: |access-date= requires |url= (help); Missing or empty |url= (help)
"BETAPACE AF (sotalol HCl)". Bayer HealthCare Pharmaceuticals Inc. {{cite web}}: |access-date= requires |url= (help); Missing or empty |url= (help)
"Announcement of Approval of Additional Indications for Onoact® 50 for Injection, Short-Acting Selective ß1 Blocker". www.evaluategroup.com. Evaluate Ltd. Retrieved 18 October 2017. {{cite web}}: no-break space character in |title= at position 52 (help)
"DailyMed - METIPRANOLOL- metipranolol solution/ drops". dailymed.nlm.nih.gov. NIH. Retrieved 18 October 2017.
"Drugs to Prevent Migraine in Adults". pharmacist.therapeuticresearch.com. Therapeutic Research Center. Retrieved 30 April 2017.
Cite error: The named reference Rossi was invoked but never defined (see the help page).

@Jytdog: I've finished the necessary citing and have moved the material over. Thank you for bringing this important issue to our attention.―Biochemistry🙴❤ 04:09, 18 October 2017 (UTC)

Thanks for taking care of that! So much work! Jytdog (talk) 05:17, 18 October 2017 (UTC)r

Expand on Other Effects

The "Other effects" section mentions beta-adrenergic mediated inhibition of melatonin secretion. It might be useful to discuss the differences in melatonin secretion inhibition between beta blockers. ―Biochemistry🙴❤ 04:11, 18 October 2017 (UTC)

Other Effects, Beta-adrenergic Receptors

Proposed addition: "Because beta-adrenergic receptors are expressed across a diverse group of cancers, researchers are exploring ways to identify tumor types that would be responsive to beta blockers." Citation: 10.18632/oncoscience.357

This section on non-cardiological indications should be supported, although this citation is admittedly primary research. Do you think this adds reliable, valuable information to this article?Cglife.trummler (talk) 23:02, 14 November 2017 (UTC)

I couldn't view the citation. Can you give a DOI?

I found a review article on the subject here, but I haven't read it. See: Coelho, M., Soares-Silva, C., Brandão, D. et al. J Cancer Res Clin Oncol. 2017;143:275.―Biochemistry🙴❤ 23:43, 14 November 2017 (UTC)

Categories: